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Abstract
RNA interference (RNAi) represents the only method currently available for manipulating gene-specific expression in
Schistosoma spp., although application of this technology as a functional genomic profiling tool has yet to be explored. In
the present study 32 genes, including antioxidants, transcription factors, cell signaling molecules and metabolic enzymes,
were selected to determine if gene knockdown by RNAi was associated with morphologically definable phenotypic changes
in early intramolluscan larval development. Transcript selection was based on their high expression in in vitro cultured S.
mansoni primary sporocysts and/or their potential involvement in developmental processes. Miracidia were allowed to
transform to sporocysts in the presence of synthesized double-stranded RNAs (dsRNAs) and cultivated for 7 days, during
which time developing larvae were closely observed for phenotypic changes including failure/delay in transformation, loss
of motility, altered growth and death. Of the phenotypes evaluated, only one was consistently detected; namely a reduction
in sporocyst size based on length measurements. The size-reducing phenotype was observed in 11 of the 33 (33%) dsRNA
treatment groups, and of these 11 phenotype-associated genes (superoxide dismutase, Smad1, RHO2, Smad2, Cav2A, ring
box, GST26, calcineurin B, Smad4, lactate dehydrogenase and EF1a), only 6 demonstrated a significant and consistent
knockdown of specific transcript expression. Unexpectedly one phenotype-linked gene, superoxide dismutase (SOD), was
highly induced (,1600-fold) upon dsRNA exposure. Variation in dsRNA-mediated silencing effects also was evident in the
group of sporocysts that lacked any definable phenotype. Out of 22 nonphenotype-expressing dsRNA treatments (myosin,
PKCB, HEXBP, calcium channel, Sma2, RHO1, PKC receptor, DHHC, PepcK, calreticulin, calpain, Smeg, 14.3.3, K5, SPO1,
SmZF1, fibrillarin, GST28, GPx, TPx1, TPx2 and TPx2/TPx1), 12 were assessed for the transcript levels. Of those, 6 genes
exhibited consistent reductions in steady-state transcript levels, while expression level for the rest remained unchanged.
Results demonstrate that the efficacy of dsRNA-treatment in producing consistent phenotypic changes and/or altered gene
expression levels in S. mansoni sporocysts is highly dependent on the selected gene (or the specific dsRNA sequence used)
and the timing of evaluation after treatment. Although RNAi holds great promise as a functional genomics tool for larval
schistosomes, our finding of potential off-target or nonspecific effects of some dsRNA treatments and variable efficiencies in
specific gene knockdown indicate a critical need for gene-specific testing and optimization as an essential part of
experimental design, execution and data interpretation.
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Introduction
Digenetic trematodes (parasitic flatworms) of the genus
Schistosoma infect more than 200 million people in over 70
developing countries [1], with an additional 770 million people
worldwide at risk of becoming infected [2]. As causative agents of
chronic, often severe morbidity and responsibility for an estimated
280,000 death per year in Africa alone [3], schistosomiasis ranks as
one of the most important of neglected tropical diseases [4].
Although significant research effort and funding have been
dedicated to the treatment and control of schistosomiasis,
including sanitary measures, suppression of the snail intermediate
host, and chemotherapeutic interventions, there has been little
change in the overall disease prevalence [5]. Progress in vaccine
development has been very slow, and although several antigens,
some of which are currently under clinical trial, have shown
limited promise in rodent and primate challenge experiments,
prospects are not good for an effective, highly protective vaccine in
the foreseeable future [6,7]. Clearly there continues to be a
pressing need for new strategies to break the cycle of schistosome
transmission to the human population [8–10].
In view of the limited options available for controlling
schistosomiasis in both the human host and snail vector, it is
important that research focus on obtaining information that can
be translated into new tools for parasite control. To that aim,
genomic, transcriptomic and proteomic approaches offer strong
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new drug candidates, and provide a better understanding of basic
molecular mechanisms underlying host-parasite interactions. The
S. mansoni Genome Project and data generated by various gene
discovery efforts using expressed sequence tags (ESTs) and serial
analysis of gene expression (SAGE), have resulted in a massive
amount of gene sequence and expression information [11–19].
However, without reliable reverse or forward genetics methods,
this vast amount of data cannot be placed into any functional
context that can then be used to determine the value or
importance of specific genes as targets for disease control.
Unlike the parasitic nematodes, which have benefited from
reverse genetic methods developed in the model free-living worm
Caenorhabditis elegans [20,21], no analogous model system is
available for schistosomes. This has further delayed the application
of new genomic technologies to problems related to disease control
and drugs development [22]. However, despite this lack of a C.
elegans-type model for parasitic flatworms, important advances
have been made in trematode transgenesis with the introduction
and transient expression of various reporter constructs in
schistosomes [22,23] and fasciolids [24], although these approach-
es did not permit the functional assessment of specifically
introduced genes. With the first demonstrations of gene expression
knockdown by RNA interference (RNAi) in the mammalian [25]
and snail [26] stages of S. mansoni, this reverse-genetics approach
has now been applied to a limited number of genes expressed in
primary (=mother) sporocysts [27], schistosomula [28,29] and
adults [30]. In a recent review of RNAi in parasitic helminths,
however, Geldhof and collaborators [31] admonish researchers
for, at times, providing insufficient data that more firmly connects
RNAi-mediated gene expression changes with specific phenotypes,
and/or reporting only on genes that are susceptible to double-
stranded (ds)RNA-mediated knockdown. Therefore, in order to
gain a broader profile of RNAi efficacy in schistosomes, in the
current study we performed an in vitro phenotypic screening of 32
genes known to be expressed in primary sporocysts of S. mansoni.
These genes covered a variety of functional categories including
antioxidants, transcription factors, cell signaling molecules and
metabolic enzymes. Out of the 32 genes (comprising 33 dsRNA
treatments) targeted for silencing, one-third (11 genes) exhibited a
dsRNA treatment-associated phenotype that consisted of a
reduction in sporocyst size (i.e., larval length). Interestingly of
the 11 phenotype-yielding genes, only 7 demonstrated a significant
and consistent alteration in transcript expression after the 7-day
treatment period, although time-course experiments suggest that
transient gene knockdown during earlier times of exposure may, in
part, account for the observed phenotype.
Materials and Methods
Schistosoma mansoni in vitro culture and dsRNA
treatments
All experiments were performed using the NMRI strain of S.
mansoni. Eggs were obtained from 7–8 weeks infected mouse livers.
After hatching in an artificial ‘‘pond water’’ [32] containing
antibiotics (50 mg/mL streptomycin and 60 mg/mL penicillin),
miracidia were immobilized on ice for 15 min, washed twice in
cold pond water by centrifugation (1 min, 7006g) and gently
resuspended in Chernin’s balanced saline solution (CBSS) [33],
supplemented with glucose and trehalose (1 g/L each), strepto-
mycin (50 mg/mL) and penicillin (60 mg/mL) [34]. Larvae were
then counted and distributed into either 48- or 96-well polystyrene
tissue culture plates (Costar, Corning Incorporated, NY) at
concentrations of ,6000 and 500 miracidia/well, respectively,
depending on the experiments being performed. The general
procedure used in all RNAi experiments involve treatment of
miracidia starting at day 0 in culture with specific dsRNAs or
control media containing irrelevant dsRNAs or medium alone for
7 days followed by assessment of an RNAi-type effect [26]. Details
of dsRNA preparation and experimental designs are presented
below. All research protocols involving mice used in the course of
this study were reviewed and approved by the Institutional Animal
Care and Use Committee (IACUC) at the University of
Wisconsin-Madison under assurance no. A3368-01.
Targeted genes
In the present study, a total of 32 genes were selected for
quantitative and qualitative assessment. Twenty-three of these
genes were chosen based on their abundant expression in in vitro
cultured S. mansoni miracidia and/or primary sporocysts, using the
SAGE database OrganismDB [18] http://gmod.mbl.edu/perl/
site/s_mansoniest]: calcineurin B (AJ276885.1), lactate dehydro-
genase (LDH; U87629.1.), Smad4 (AY371484.1.), Smad2
(AF232025.1), Smad1 (AF215933.1), 14.3.3 (U24281.1), epider-
mal growth factor receptor (Scmeg; M86399.1), phosphoenolpyr-
uvate carboxykinase (PepCK; AF120929.1), calpain (M74233.1),
hexamer-binding protein (HEXBP; putative, organismDB:-
Tag623), fibrillarin (putative, OrganismDB: Tag 428), elongation
factor 1a (EF1a; Y08487.1), Rho 1 GTPase (Rho1; AY158212.1),
Rho 2 GTPase (Rho2; AY158214.1), calcium ATPase 2, (Sma2;
AF074400.1), SPO1 (AF109181), protein kinase Cß (PKCß;
AY337620.1), protein kinase C receptor (PKC receptor;
AF422164.1), zinc finger DHHC domain (DHHC; putative,
OrganismDB: Tag 1180), myosin-light chain (AF071011.1),
calreticulin (L24159.1), high voltage-activated calcium channel
subunit a (Cav2A; AF361883.1) and high voltage-activated
calcium channel ß-subunit 2 (calcium channel; AY277532.1).
The remaining 9 genes were chosen for their predicted putative
functions in the parasite (antioxidants, transcription factors) and
Author Summary
RNA interference (RNAi) represents the only method
currently available for manipulating gene-specific expres-
sion in human blood flukes, Schistosoma spp., although its
application as a functional genomics tool in early
intramolluscan larval stages has been limited to single
gene analyses. Accelerating gene discovery efforts over
the past 10 years have resulted in extensive, ever-
increasing databases of genomic, transcriptomic and EST
sequences. Unfortunately, our understanding of the
function of the vast majority of these genes has not kept
pace with their discovery, and this represents a significant
barrier and the next real challenge for investigators of
schistosomes, and other parasitic helminths. In the present
study, we selected an array of 32 genes expressed in S.
mansoni sporocysts to evaluate their susceptibility to
double-stranded (ds)RNA treatment and to begin charac-
terizing morphological phenotypes associated with a
potential RNAi effect. Results demonstrate that gene
knockdown and/or resulting phenotypes are highly
transcript-dependent (specific dsRNA sequence used) and
vary with time post-dsRNA exposure. Because of this
potential variability in both transcript and phenotype
expression in response to dsRNA treatment, our findings
illustrate that, although a RNAi-type approach holds great
promise as a functional reverse-genetics tool for larval
schistosomes, its application requires caution in the design
and execution of experiments and interpretation of results.
RNAi in Larval Schistosomes
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(AY903301.1), zinc finger 1 (SmZF1; AF316827.1.), ring box
(SmRbx; DQ466078.1.), glutathione peroxidase (GPx; M86510.1),
thioredoxin peroxidase 1 (TPx-1; AF121199.1), thioredoxin
peroxidase 2 (TPx-2; AF157561.1), superoxide dismutase (SOD;
M27529.1), 26 kDa glutathione-S-transferase (GST26; M73624.1),
and 28 kDa glutathione-S-transferase (GST28; S71584.1). TPx-1
and TPx-2 were used in combination to simultaneously silence both
thioredoxin peroxidases. All of the above sequences are available
from GenBank (http://www.ncbi.nlm.nih.gov/Genbank) or Orga-
nismDB as indicated above.
Double-stranded (ds) RNA synthesis
T7 promoter-tagged specific PCR primers were designed to
amplify ,500 base pair (bp) products for each of the targeted
genes (Dataset S1; Table 1). A 500-bp green fluorescent protein
(GFP) gene segment also was synthesized from the vector pAcGFP
(Clontech, Mountain View, CA) to serve as a nonspecific dsRNA
treatment-control. Following amplification, PCR products were
separated on 1% agarose gels and purified using QIAquick gel
extraction kit (Qiagen, Valencia, CA), following the manufactur-
er’s protocol. Each PCR product was sequenced and their
sequences verified using the Basic Local Alignment Search Tool
(BLASTn, National Center for Biotechnology Information,
NCBI). Double-stranded RNAs were synthesized from isolated
sporocyst cDNA using T7 RiboMAX Express RNAi Kit
(Promega, Madison, WI), according to procedures outlined by
the manufacturer. Briefly, dsRNAs synthesis reactions were
allowed to incubate for 16 hr at 37uC prior to DNAse treatment.
DsRNA products were then phenol/chloroform-extracted and
purified by precipitation with isopropanol. The purified products
were resuspended in diethylpyrocarbonate (DEPC)-treated water,
quantified by measurement at OD260 and their integrity verified
by 1% agarose gel electrophoresis. Samples were stored at 220uC
until further use.
Phenotypic screening and dsRNA uptake experiments
Effects of dsRNA treatment on in vitro cultured S. mansoni larvae
were performed in 96-well culture plates (Costar) in which
approximately 500 miracidia were added to wells containing
50 nM of specific or control green fluorescent protein (GFP)
dsRNA diluted in 200 mL CBSS or medium lacking any dsRNA
(no dsRNA control). Cultures were maintained at 26uC for 4 days,
after which time an additional 10 nM of dsRNA was added to
each well due to possible RNA degradation in culture [35],
followed by incubation for 3 more days. Over the 7 days culture
period, sporocysts were monitored for the following phenotypes:
failure/delay in transformation, loss of motility, tegumental lysis
and granulation (lethality) and changes in larval growth. Parasite
viability and morphological changes were monitored daily using a
Nikon Eclipse TE 300 inverted epifluorescent microscope (Nikon
Instrument Inc., Melville, NY). In addition digital images of live
treated and control parasites were captured using a CoolPix EZ
digital camera (Nikon Instruments Inc.) throughout the 7-day
incubation period, allowing more detailed observations of larval
morphology and to quantify sporocyst growth (length measure-
ments) in treated vs. control larvae at day 7. Length measurements
from captured images were obtained and analyzed by Metamorph
software version 7.0 (Meta Imaging series, Molecular Devices,
Sunnyvale, CA). Sporocysts exhibiting tegumental lysis or loss of
surface/somatic integrity were excluded from measurements.
Larval growth datasets for each experimental replicate were
statistically analyzed using the Mann-Whitney U-test (Wilcoxon-
Sum of Ranks test) with significance set at P#0.05. All treatments
were performed in duplicate wells, and the experiment was
independently replicated a minimum of 3 times on miracidia
isolated from different batches of infected mouse livers. In
addition, to verify dsRNA uptake by sporocysts we labeled
Smad4, lactate dehydrogenase and GFP (specificity control)
dsRNAs with rhodamine using the Label IT kit (CX-Rhodamine
Labeling Kit; Mirus, Madison, WI), according to manufacturer’s
recommendations. Miracidia were in vitro-transformed to sporo-
cysts in CBSS containing 50 nM labeled dsRNAs and subjected to
epifluorescence photomicrography after 7 days of incubation.
Effect of dsRNA treatment on larval gene expression
In order to demonstrate an association between phenotype and
transcript expression real-time quantitative PCR (q-PCR) was used
to determine steady-state transcript levels in specific dsRNA-treated
sporocysts. In these experiments ,6000 miracidia were distributed
into a 48-well plate (Costar) and treated with 50 nM dsRNA diluted
in CBSS (500 mL/well). Cultures were maintained at 26uC for 2, 4
or 7 days prior RNA extraction and isolation. Cultures maintained
for 7 days were supplemented with 10 nM dsRNA at day 4.
SporocystswereextensivelywashedwithCBSSinordertoeliminate
unabsorbed dsRNAs and shed ciliary epidermal plates, followed by
extraction in Trizol reagent (Invitrogen, Carlsbad, CA) to isolate
both total RNA and protein fractions from cultured larvae. The
protein pellet was dissolved in the protein solubilization buffer (3 M
Urea, 2% CHAPS, 40 mM Tris) for use in Western blot analyses
(see below), while the isolated RNA fraction was resuspended in
DEPC-treated water and subjected to DNAse treatment using the
DNA-Free kit (Ambion, Austin, TX) to eliminate any contaminat-
ing genomic DNA. RNA samples were quantified and their purity
assessed on a Nanodrop Spectometer ND-1000 (NanoDrop
Technologies, Inc., Wilmington, DE).
Real-time quantitative PCR (q-PCR) analysis
Quantitative PCR analysis was used to compare steady-state
transcript levels between specific dsRNA-treated sporocysts and
control treatments (GFP-dsRNA). To accomplish this 0.5 to 1 mg
total RNA, derived from at least three different extractions, was
used to synthesize cDNA using Superscript III cDNA Synthesis kit
(Invitrogen, Carlsbad, CA) following the manufacturer’s protocol.
The q-PCR reaction mixtures consisting of 2.5 mL of cDNA,
12.5 mL of Sybr Green PCR Master Mix (Applied Biosystems,
Foster City, CA), 10 mL of 600 or 900 nM primers (determined
after primer concentration optimization), were added to 96-Well
Optical Reaction Plates (ABI PRISM, Applied Biosystems) for
amplification and quantification in a AB7500 Real Time PCR
System (Applied Biosystems). In order to avoid the possibility of
false amplification of the originally applied dsRNA, specific pairs
of primers were designed outside of the region used to synthesize
the original interfering dsRNA products (Dataset S1; Table 2). In
addition to the targeted gene-specific primers used to assess
potential knockdown, primers for S. mansoni glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) and a-tubulin were used as
endogenous normalization controls in all samples tested. Other
controls for verifying the specificity of RNA treatment effects
included (1) larval treatment with irrelevant GFP dsRNA and (2)
treatment with a nontarget S. mansoni dsRNA. Finally, each q-PCR
run was performed with 2 internal controls assessing both potential
genomic DNA contaminations (no reverse transcriptase added)
and purity of the reagents used (no cDNA added). For each
specific set of primers, all individual treatments (including
specificity controls) were run in three technical replicates. Each
experiment was repeated 3–5 times (N=3–5) as independent
biological replicates and the DDCt method [36], using GAPDH
RNAi in Larval Schistosomes
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quantification of all cDNA targets was used to quantitatively
compare treatment and control steady-state transcript levels. Due
to the nonparametric distribution of data, statistical analysis of
DDCt values was performed using the Mann-Whitney U-test with
significance set at P#0.05.
Effect of specific dsRNA treatment at the protein level
Using a sporocyst-reactive rabbit anti-elongation factor 1a (anti-
EF1a) antibody (Cell Signaling Technology, Danvers, MA),
Western blot analysis and immunocytochemical localization
experiments were performed to monitor EF1a protein levels in
EF1a dsRNA-treated sporocysts. For Western blots miracidia,
transformed in the presence of 50 nM EF1a or control GFP
dsRNA and cultivated in vitro for 7 days, were extracted in Trizol
reagent (Invitrogen) as previously described, separated by standard
12.5% SDS-PAGE methods [37], and electroblotted to nitrocel-
lulose membranes (Biorad Lab, Richmond, CA) using a semi-dry
protein transfer apparatus (Hoefer TE 70, Amersham Biosciences).
After transfer, membranes were blocked overnight in TBS (2.42 g
Tris base and 8 g NaCl/L, pH 7.6) containing 5% bovine serum
albumin (BSA), followed by incubation in a mixture of anti-EF1a
(1: 1000) and rabbit anti-SmGST26 (loading control, 1:1000
dilution; Cell Signaling Technology), for 16 hr at 4uC. Mem-
branes were washed 3 times in TBS-Tween (0.1%) and incubated
for 1 hr in TBS 5% BSA containing either goat anti-rabbit IgG-
alkaline phosphatase-tagged (AP) or AP-labeled goat anti-rabbit
IgG (1:10
4 and 1:5000, respectively). Colorimetric immunoreac-
tivity was detected with the chromogen substrate 5-bromo-4-
chloro-3-indolyl phosphate (BCIP) and nitro-blue tetrazolium
(NBT), diluted in AP buffer (0.1 M Tris, 0.1 M NaCl, 0.05 M
MgCl2, pH 9.5). To quantify the relative levels of anti-EF1a in
specific dsRNA- and control GFP dsRNA-treated sporocyst
extracts, target and control immunoreactivities were measured
using an Ultraviolet Trans-illuminator BioImaging Systems (UVP,
Inc., Upland, CA) with the co-processed anti-GST26 band serving
as a normalizing signal (loading control). Quantitative compari-
sons of protein expression for EF1a in control and target dsRNA-
treated sporocysts were analyzed by LabWorks Image Acquisition
and Analysis Software version 4.6.
For immunocytochemical studies, 7-day old dsRNA-EF1a or -
GFP-treated sporocysts were washed in CBSS (allowing removal of
ciliated epidermal plates), transferred to siliconized-microcentrifuge
tubes in 500 mL PT buffer (2% paraformaldehyde, 1% Triton-
X100/sPBS), and incubated overnight at 4uC with constant rotation.
Fixed-parasites were washed 5 times in sPBS by centrifugation at
1600 rpm (2 min), resuspended in 500 mL of blocking buffer (5%
normal goat serum/0.02% azide/sPBS) for 16 hr, under constant
agitation before addition of rabbit-anti-EF1a primary antibodies
(1:200 dilution in blocking buffer) and incubation overnight at 4uC.
Parasites were washed for 10 min in sPBS, resuspended in 500 mLo f
AlexaFluor 488-conjugated goat anti-rabbit IgG (4 mg/mL blocking
b u f f e r )a n di n c u b a t e df o r1 6h ra t4 uC with agitation. Following
antibody treatments, sporocysts were washed 5 times in sPBS by
centrifugation (1600 rpm, 2 min), resuspended in 40 mLo fs P B Sa n d
mountedoncoverslips.Specimenswereexaminedandphotographed
using a Nikon Eclipse TE2000 (Nikon Instrument Inc.) inverted
microscope equipped with a Bio-Rad Radiance 2100 MP Rainbow
Confocal/Multiphoton Imaging System (W.M. Keck for Biological
Imaging, Instrumentation, UW-Medical School).
Results
In our initial phenotype analysis of 24 different dsRNA
treatments, no differences between specific dsRNA-treated larvae
and controls (GFP dsRNA-treated and untreated sporocysts) were
Figure 1. In vitro cultured S. mansoni larvae 7 days post-dsRNA treatments. Brightfield photomicrographs of in vitro cultured Schistosoma
mansoni sporocysts after 7 days of treatments with a specific GST26-dsRNA (A) compared to the control GFP-dsRNA (B), illustrating the effects of
exposure to phenotype-inducing GST26-dsRNA on sporocyst lengths. Arrows indicate examples of shortened (white arrows) and normal elongate
(black arrows) sporocysts measured in both treatments. Asterisks indicate rounded ciliated epidermal plates that were shed from the miracidial
surface after transformation.
doi:10.1371/journal.pntd.0000502.g001
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(mm) after 7 days of dsRNA treatments, from 3 independent experiments (A–C). Sporocyst length measurements are represented by scatter plots with
the calculated median values indicated by the horizontal bars within each dsRNA treatment. The median values for specific dsRNA treatments were
compared to both GFP-dsRNA (green plots) and blank (no dsRNA; blue plots) treatment controls. For each of the 3 experiments, the pair of controls is
shown in between solid and dashed vertical black lines, immediately followed by the gene-specific dsRNAs groups. The dsRNA treatments exhibiting
significant differences from GFP and blank controls in all 3 replicate experiments are represented as colored plots, marked with an asterisk (Smad4,
lactate dehydrogenase, Smad2, Cav2A, EF1a, Smad1, RHO2, calcineurin B, and ring box), while those yielding inconsistent phenotypic differences
when compared to the controls (myosin, PKCB, HEXBP, SmZF1, calcium channel, Sma2, RHO1, PKC receptor, DHHC, Pepck, calreticulin, calpain, Smeg,
14.3.3, and K5) are indicated by black dot scatter plots. Of this latter group, asterisks denote those individual replicates that were significantly
different from controls. All treatments were statistical analyzed using Mann-Whitney U-test within each experiment, *P#0.05.
doi:10.1371/journal.pntd.0000502.g002
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mortality during the in vitro cultivation period. The only notable
phenotype observed in treated 7-day cultured sporocysts was an
apparent greater number of small-sized or shortened sporocysts
possibly involving a growth-related defect(s) (Fig. 1A, 1B).
However, because sporocysts in a given culture population
typically represented a range of sizes, live sporocyst images were
captured, from which larval lengths were measured and digitally-
analyzed using Metamorph software. Within each biological
replicate, such measurements were taken for the dsRNA treatment
groups and statistically compared to both the GFP dsRNA-treated
and no treatment (blank) groups. For a given dsRNA to be
identified as having a putative dsRNA-mediated effect, the median
larval length had to significantly differ (P#0.05) from both the
GFP dsRNA and the blank controls in each of the biological
replicates. Using these criteria, we observed significant decreases
in parasite lengths in 9 of 24 dsRNAs in the first screening trial:
Smad4, lactate dehydrogenase (LDH), Smad2, Cav2A, elongation
factor 1a (EF1a), Smad1, RHO2, calcineurin B, and ring box
(Fig. 2). Similar results were found in a second experimental series,
which included nine additional dsRNA treatments. In this case,
using the same criteria for significance, 2 of the 9 dsRNAs
treatments (GST26 and SOD) exhibited a consistent size-related
phenotype effect when compared to controls (Fig. 3). As before,
greater frequency of shortened larvae was the only observable
dsRNA-associated phenotype.
To illustrate the variability in parasite response to the different
dsRNA at the population level, and to underscore the importance
of biological replication in phenotypic analysis of dsRNA
treatment effects, 9 of the 33 dsRNA treatments (Scmeg, HEXPB,
Sm zinc finger1 (SmZF1), -calpain, -myosin light chain, PKCß,
SPO1, TPx1/2 and calcium channel) exhibited significant length
decreases in 2 of 3 experiments suggesting a possible, but
inconsistent, connection with the observed phenotype. Sporocyst
treatment by the remaining dsRNAs (14-3-3 protein, Sma2,
RHO1, PKC receptor, DHHC, PEPCK, calreticulin, glycopro-
tein K5, fibrillarin, GST28, GPx, TPx1, and TPx2) had no
measurable effect on larval phenotype (Figs. 2 and 3).
In order to document potential difference in dsRNA uptake
within larval populations and between treatments, miracidia were
exposed to rhodamine (Rh)-labeled dsRNA-GFP, -Smad4 or –
LDH. After 7 days of exposure, dsRNA-uptake in sporocysts was
assessed by fluorescent microscopy. As shown in Figure 4, larvae
within a single population exhibited wide variation in their abilities
to take up labeled dsRNA, regardless of transcript species (Figs. 4A
and B). Indeed, a one-way ANOVA comparing the 3 dsRNA-
treated groups for the prevalence of tegumental or internal staining
was non-significant (F=1.159; P=0.2555) indicating no differences
in staining distribution between groups or locations. The most
prominent sites of Rh-dsRNA localization in positively-stained
sporocysts (67% of larvae) were in the tegument (,28%), excretory
pores/flame cellsandinunidentifiedparenchymal-likecells (,39%)
Figure 3. Additional S. mansoni sporocyst length measurements 7 days post-dsRNA treatments. Graphic representation of sporocyst
lengths (mm) after 7 days post-dsRNA treatments, generated from 3 independent experiments covering an additional group of sporocyst-expressed
genes. Larva lengths are represented by a dot scatter plots with the median length for each sporocyst treatment group shown as a short horizontal
bar. Calculated medians for each target dsRNA group were compared to both GFP-dsRNA (green dots) and no-dsRNA (blank, blue dots) control
median values. For each experiment, controls are the first 2 scatter plots shown between the solid red and black vertical lines, followed by the 2
dsRNA treatments that showed significant phenotypic differences in all 3 experiments (marked with *; GST26 and SOD) when compared to both
controls. Black scatter plots represent dsRNA-treated sporocysts whose median length measurements exhibited inconsistent differences when
compared to both GFP and blank controls. Of this latter group (TPx1/2, fibrillarin, GST28, GPx, TPx2, TPx1, and SPO1), asterisks denote those individual
replicates that were significantly different from controls. Each experiment was analyzed using Mann-Whitney U-test, *P#0.05.
doi:10.1371/journal.pntd.0000502.g003
RNAi in Larval Schistosomes
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unlabeled-dsRNA did not display any fluorescent signal (data not
shown). Sporocysts within a given population exhibited heteroge-
neous (+/2) Rh-staining indicating specific dsRNA uptake by
larvae, and not a nonspecific uptake via Rh-binding.
Because the phenotypic screen revealed both phenotype-
associated and nonphenotype-associated dsRNA species, we
selected a subset of 24 genes to assess the effect of dsRNA
treatments on steady-state transcript levels using real-time
quantitative PCR (q-PCR). Comparisons of normalized-levels of
dsRNA-targeted messenger RNAs to their corresponding control
treatment (GFP dsRNA-treated group) resulted in 12 transcripts
that exhibited significantly reduced expression levels (Fig. 5).
Unexpectedly, SOD transcripts consistently increased, rather than
decreased, to very high levels of expression (.1600-fold) upon
specific dsRNA treatment.
A comparison wasmade between dsRNAspecies that produced a
detectable phenotype and those generating a significant transcript
knockdown (or induced expression) in an attempt to directly
correlate phenotype and gene expression. Notably, only 7 of the 11
target dsRNA-treatments that produced a ‘‘shortened’’ larval
phenotype presented a significant alteration in transcript levels
(Smad4, lactate dehydrogenase, Cav2A, EF1a, calcineurin B,
GST26 and SOD) when compared to dsRNA-GFP treated
sporocysts (Fig. 5). Smad4 and LDH dsRNA treatments showed a
small, but consistently significant 15% decrease, while Cav2A,
calcineurin B, EF1a and GST26 exhibited knockdowns of 42%,
65%, 70% and 85%, respectively. SOD, whose transcript levels
were dramatically increased in dsRNA-treated sporocysts, also was
phenotype-associated. In addition, as noted in Figure 5, 6 dsRNA
treatment groups that did not exhibit significant or consistent
changes in larval length expressed significantly lower transcript
levels than controls ranging from an approximately 30% (SmZF1)
to 75% (fibrillarin, GST28, GPx, TPx1, and TPx2) after 7 days of
exposure. No changes in transcript levels were observed for
phenotype-associated Smad1, Smad2, RHO2 and ring box dsRNA
Figure 4. Localization of rhodamine-labeled-dsRNA in S. mansoni larvae 7 days post-exposure. Brightfield (A) and fluorescent (B)
photomicrographs showing S. mansoni sporocysts and localization of rhodamine-dsRNA taken up after 7 days of labeled dsRNA exposure,
respectively (1006). Arrowheads indicate rounded epidermal plates that were shed from miracidia during transformation to sporocysts. (B)
Fluorescent images show the different levels of dsRNA penetrance within the same treatment and the same population. (C) The higher magnification
(4006) illustrating the heterogeneity of dsRNA uptake within individual sporocysts in a given population including excretory ducts/flame cells (FC),
cells within the parenchyma (PC), and tegument (T).
doi:10.1371/journal.pntd.0000502.g004
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calpain, 14.3.3 protein, glycoprotein K5, and SPO1 dsRNAs.
Since we typically used day 7 as our temporal end-point for
assessing RNAi phenotypic effect, we also investigated the
possibility that transcripts may have been knocked down prior to
day 7. Using a subsampling of dsRNA species that represented a
range of transcript knockdown levels, S. mansoni miracidia were
treated with dsRNA-EF1a, -calcineurin B, -SOD, -LDH, -RHO2,
-Smad2 -Smad4, myosin light chain and -ring box, and sporocyst
transcript levels analyzed after 2 and 4 days postexposure.
Compared to our previous 7-day treatment effects, results yielded
various patterns of transcript silencing (Fig. 6). For example,
although EF1a and calcineurin B transcripts were significantly
reduced by ,70% by day 7, calcineurin B knockdown was
actually greatest (,90%) at 2 days postexposure to dsRNA. Smad4
and LDH mRNAs, which previously showed a small, but
significant, decrease at day 7 exhibited highest knockdown
(,40%) on day 2 indicating an early effect of dsRNA treatment.
SOD was found to be over-expressed at all time points, with an
initial increase of ,1200% at day 2, followed by a maximum
,17,000-fold expression at day 4, before again returning to day-2
levels after 7 days of exposure. SOD transcript levels, however,
were unaffected by heterologous exposure of larvae to several non-
SOD-related dsRNAs (data not shown). RHO2 dsRNA, previ-
ously displaying no effect on homologous transcript expression in
sporocysts at 7 days, showed significant transcript knockdown at 2
and 4 days post-exposure before recovering to control levels at the
7-day time point. In contrast, Smad2, myosin light chain and ring
box dsRNA treatments demonstrated no consistent effect on their
respective transcript levels regardless of the sampling interval.
Finally, because we had available an antibody that was
specifically reactive to the S. mansoni EF1a protein, we assessed
the effect of EF1a dsRNA treatment on EF1a protein levels using
Western blot and immunofluorescence imaging. Western blot
analysis clearly showed that EF1a dsRNA-treated 7-day sporocyst
extracts were significantly reduced in EF1a protein (50 kDa band)
compared to the GFP dsRNA-treated control group (Fig. 7). The
presence of a 25 kDa GST26 band (used as an antibody specificity
and loading control) in both the EF1a and GFP dsRNA-treated
samples suggested both a specific EF1a transcript silencing and
associated protein knockout (Fig. 7). This result was quantitatively
confirmed bydensitometryshowingthat,followingnormalization of
transcripts to the loading control, EF1a protein was highly reduced
by.80%intheEF1a dsRNA-treated samplecomparedtothe GFP
dsRNA control. Confocal immunolocalization of EF1a in intact
dsRNA-treated sporocysts was consistent with the Western blot
analysis: EF1a dsRNA-treated larvae displayed little immunoreac-
tivity, while abundant anti-EF1a-reactivity was evident within cells
and parenchymal tissues of GFP dsRNA-treated sporocysts (Fig. 8).
Discussion
RNA interference (RNAi) has been widely used in a variety of
organisms as a reverse-genetic approach to generate functional gene
Figure 5. Transcript levels of dsRNA-treated sporocysts 7 days after dsRNA exposure. Bar graph depicting the relative steady-state
transcript levels of dsRNAs-treated sporocysts after 7 days of exposure compared to the GFP-dsRNA control. For each dsRNA tested, data are
represented as mean fold-differences (+/2S.E.) relative to the GFP control (1.00). Colored bars represent sporocyst mRNA levels showing consistent
and statistically significant decrease (dsRNA-Smad4/GFP, P=0.0056; -lactate dehydrogenase/GFP, P=0.0358; -Cav2A/GFP, P=0.0136; -EF1a/GFP,
P=0.0358; -calcineurin B/GFP, P=0.0189; -GST26/GFP, P=0.0136; -SmZF1/GFP, P=0.0189; -fibrillarin/GFP, P=0.0407; -GST28/GFP, P=0.0284; -GPx/
GFP, P=0.0269 and -TPx1/GFP, P=0.0358/-TPx2/GFP, P=0.0358) or increase (dsRNA-SOD/GFP, P=0.0294) in target transcript levels when compared
to the GFP-dsRNA control treatment. Tan-colored bars represent transcript levels for dsRNA-treated sporocysts that showed no differences when
compared to GFP-dsRNA treated controls (-Smad2/GFP, P=0.0755; -Smad1/GFP, P=0.8969; -RHO2/GFP, P=0.0765; -ring box/GFP, P=0.7642; -
myosin/GFP, P=0.3725; -PKCB/GFP, P=0.6579; -PEPCK/GFP, P=0.3017; -calpain/GFP, P=0.1642; -14.3.3/GFP, P=0.6579; -K5/GFP, P=0.3725 and -
SPO1/GFP, P=0.8969). In addition, bars located on the left of the solid red vertical line represent treated-sporocysts previously shown to express the
shortened phenotype (dsRNA-Smad4, -lactate dehydrogenase, -Smad2, -Cav2A, -EF1a, -Smad1, -RHO2, -calcineurin B, -ring box, -GST26 and -SOD).
Transcript levels were determined by q-PCR and data analyzed using the DDCt method [36] followed by statistical analysis using the Mann-Whitney
U-test. Significance levels were set at P#0.05. Data were generated from 3–5 independent experiments.
doi:10.1371/journal.pntd.0000502.g005
RNAi in Larval Schistosomes
www.plosntds.org 8 August 2009 | Volume 3 | Issue 8 | e502knockdowns with associated phenotypic changes [38–40]. In
combination with complete and well-annotated genome databases,
tools developed for RNAi now permit systematic, whole-genome
screening leading to putative functional assignments for unknown
genes, or direct functionalconfirmation ofgenesidentified by sequence
homology (orthologues) [41]. Some RNAi libraries are already
available and have taken advantage of this functional genomics
approach including for D. melanogaster [39] and C. elegans [42,43].
However, many newly-defined functions for any given gene tend to be
organism-specific and may not always be identical to, or even
homologous with, a similar gene’s function in other species. Therefore,
one of the current challenges we face is to integrate this organism-
specific RNAi-derived functional information into the existing, ever-
growing genomic databases of diverse organisms [44]. In addition, as
noted by Geldhof [31], application of RNAi approaches to parasitic
helminths have at times lacked convincing evidence of an RNAi effect
or have not provided information on the full spectrum or diversity of
target transcript susceptibilities to dsRNA treatments.
The RNAi screening approach described in the current study,
to our knowledge, is the first to profile morphological phenotypes
associated with exposure of larval schistosome blood flukes to
dsRNAs representing a diversity of expressed genes. From our
sampling of dsRNAs for 32 different S. mansoni genes known to be
expressed in primary sporocysts, only 34% (11 transcripts)
produced a consistent, highly reproducible phenotype; namely a
reduced larval length (shortening), morphologically resembling a
type of growth inhibition. Interestingly, this was the same
phenotype that was observed in an earlier study involving
dsRNA-mediated knockdown of a CD36-like scavenger receptor
at the tegumental surface of S. mansoni sporocysts [27]. Thus, the
genes associated with this phenotype are quite varied, including
signaling molecules, Ca-interactive proteins, redox enzymes and a
membrane receptors/ion channels. Although it would be prema-
ture to speculate on specific gene-phenotype linkages, it may not
be particularly surprising that such a general phenotype as larval
size might be regulated by many different genes expressed in
variety of cell or tissue-types. In whole genome RNAi studies of C.
elegans, an overall ,2% of detectable viable phenotypes were
growth- or size-related [41] and recent RNAi applications on
schistosomules, miracidia, or adults also produced a similar
Figure 6. Transcript levels in S. mansoni sporocysts at different times post-dsRNA treatment. Time-course of steady-state transcript levels
was assessed in sporocysts treated with dsRNAs under culture conditions. Sporocysts were treated with dsRNA-EF1a, -calcineurin B, -SOD, -lactate
dehydrogenase, -RHO2, Smad2, -Smad4, -myosin and -ring box for 2 days (stippled bars) or 4 days (gray bars), and compared to 7 day dsRNA
treatment effects (black bars). Transcript levels were assessed by q-PCR at each time and compared to its matched GFP-dsRNA control. For each
dsRNA tested, data are represented as mean fold-difference (+/2S.E.) relative to the GFP control (1.00). However, statistical analyses were based on
raw q-PCR values using the DDCt method followed by statistical analysis using the Mann-Whitney U-test, N=4, *P#0.05. Two-day comparisons
(stippled bars): dsRNA-EF1a/GFP, P=0.028; -calcineurin B/GFP, P=0.021; -SOD/GFP, P=0.015; -lactate dehydrogenase/GFP, P=0.041; - RHO2/GFP,
P=0.021; –Smad4/GFP, P=0.028; -ring box/GFP, P=0.3; -Smad2/GFP, P=1.0; and -myosin/GFP, P=0.059. Four-day comparisons (gray bars): dsRNA-
EF1a/GFP, P=0.0319; -calcineurin B/GFP, P=0.03; -SOD/GFP, P=0.028; -lactate dehydrogenase/GFP, P=0.029; - RHO2/GFP, P=0.021; –Smad4/GFP,
P=0.0286; -ring box/GFP, P=0.884; -Smad2/GFP, P=0.98; and -myosin/GFP, P=0.9. Data for 7 day dsRNA treatments (black bars) were taken from
identically performed experiments (data shown previously in Fig. 5), and are reproduced in Fig. 6 for graphic comparisons only. Statistics for this
group of genes are provided in the Fig. 5 legend.
doi:10.1371/journal.pntd.0000502.g006
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proportion of sporocyst exhibited the shortened phenotype might
be explained, at least in part, by results of the rhodamine-labeled
dsRNA uptake experiment demonstrating that ,67% of dsRNA-
treated larvae within a population (in all treatments) exhibited
signs of labeling, and of those, cellular localization of Rh-dsRNA
within sporocysts varied considerably (tegument, flame cells,
parenchymal tissues). Thus the degree and site of dsRNA
penetrance may be among several critical determinants influenc-
ing the observed phenotype. Moreover, this differential dsRNA
uptake also could explain the variation in the levels of transcript
knockdown observed in q-PCR analyses.
Attempts to correlate phenotype and knockdown of target gene
expression also yielded variable results in that 7 of the 11 genes
associated with the shortened phenotype were significantly altered in
their expression after the treatment period. One explanation as to
why all phenotype-expressing transcripts were not reduced is the
possibility that some genes possess different kinetic profiles (i.e., may
have exhibited knockdown prior to day 7). Of 5 genes whose
transcript levels were unaffected (Smad2, Rho2, ring box) or
marginally affected (Smad4, LDH) by dsRNA at 7-days of treatment,
3 transcripts (Rho2, Smad4 and LDH) showed an early significant
knockdown at day 2 suggesting a temporal reduction in transcript
levels that could be phenotype-associated. Why transcript expression
of the other 2 phenotype-associated genes (Smad2 and ring box) was
not affected by specific dsRNA treatments remains unclear, although
RNAi off-targeting, i.e., a mis-targeting of specific dsRNA to other
unidentified mRNAs [46–49] could be involved. Off-target effect of
introduced dsRNAs seems to be a common occurrence in helminth
RNAi experiments, and presents a challenge in controlling such
effects, as recently reviewed by Geldhof and colleagues [31]. Yet, it
has been shown in mammal cells that knockdown efficiency is highly
dependent on the specific dsRNA sequence of a particular gene [50],
and that in some cases, a small degree of similarity may invoke off-
target gene silencing [51]. In our current study, we exposed larvae to
gene-specific long (500 bp) dsRNA, which, upon dicer cleavage,
results in short unpredictable RNA sequences that represent potential
sources of off-target gene silencing. To complicate matters further,
some siRNA also have been shown to exhibit nonspecific toxic effects
that may directly affect transcriptional processes without altering
specific transcript levels [52].
Although it was not the goal of this study to provide in-depth
analyses of each the gene investigated herein, followup experiments
involving S. mansoni elongation factor 1a (EF1a) illustrates the
importance of providing several lines of evidence of an RNAi effect.
In this case, larval treatment with EF1a dsRNA resulted in a
demonstrable phenotype, specific transcript knockdown, and ap-
proximately 80% inhibition of EF1a protein expression as measured
by both Western blot and immunocytochemical assays. Elongation
factors are known to be essential in the translational process by
functioning to catalyze the aminoacyl-tRNA delivery to ribosomes
during protein elongation [53]. Given this putative function of EF1a,
and its widespread knockdown at the transcript and protein levels, its
involvement either directly or indirectly in generating the shortened
larval phenotype is supported by the data presented here. Reasons
w h yw ed i dn o ts e ea n yc h a n g e si nG S T 2 6p r o t e i nl e v e l si nt h eE F 1 a
Western blot assay maybe due to a slow protein turnover rate for
GST26 or the possibility that GST26 is synthesized in cells/tissues
that were unaffected by EF1a dsRNA knockdown.
Variation in dsRNA treatment effects also was evident in the
group of sporocysts that lacked any definable phenotype. Of the 13
nonphenotype-expressing larval groups, half (6) exhibited consis-
tent, significant reductions in transcript levels as measured by q-
PCR, while transcript levels in the other half (7) were unaffected.
This type of result is not unexpected as this has been demonstrated
previously in RNAi screens of model organisms such as C. elegans
[54], as well as parasitic nematodes [31,55]. For those transcripts
whose expression was unaffected by specific dsRNA treatment,
there would not be an a priori expectation of phenotypic change.
There are several ways to potentially explain a lack of differential
phenotype in larvae presenting with dsRNA-induced transcript
knockdown : (1) the gene targeted for dsRNA knockdown is
functionally unrelated to the observed phenotype, (2) since
typically an RNAi-like effect does not lead to a complete gene
(and presumably protein) knockout, sufficient protein synthesis/
activity remains to continue support of the normal ‘‘phenotype’’,
Figure 7. Quantification of differential EF1a protein levels in S.
mansoni sporocysts post-dsRNA exposure. Western blots of SDS-
PAGE separated total proteins extracted from sporocysts treated for 7
days with elongation factor1a (EF1a) or GFP (control) dsRNA. A rabbit
anti-EF1a was used to detect a 50 kDa S. mansoni EF1a, while a rabbit
anti-SmGST26 antibody served as both a protein specificity and loading
control. Note the presence of EF1a protein in dsRNA-GFP treated-
sporocysts, but reduced reactivity in EF1a-dsRNA-silenced parasites.
Significant knockdown of EF1a protein in EF1a dsRNA-treated parasites
was confirmed by optical densitometry comparing protein band
intensities of test and control dsRNA treatment groups after anti-
GST26 normalization of each band. The bar graph shows an 80%
reduction (+/2S.E.) in dsRNA-induced EF1a protein level in EF1a dsRNA-
treated sporocysts relative to GFP controls. Statistical analyses were
performed using Students t-test. *P#0.05; N=3.
doi:10.1371/journal.pntd.0000502.g007
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or replacing the protein (and its function) initially targeted for
dsRNA-mediated silencing, and (4) the protein product of the
targeted transcript may have a lengthy half-life (i.e., slow turnover
rate), hence delaying potential gene knockdown effects at the
protein level. These results further underscore the wide variation
in susceptibilities of individual S. mansoni genes to RNAi
procedures, and the fact that dsRNA knockdown may not be
associated with any demonstrable phenotype.
One of the more intriguing results of our study was the
consistent, high level upregulated expression of SOD in sporocysts
upon treatment with SOD dsRNA. Even more impressive than the
1600-fold transcript expression following the standard 7-day
incubation period was the ,17,000-fold expression 2 days earlier
(day 4). At present we do not have an explanation as to how larval
exposure to SOD dsRNA may be triggering such high expression
levels. One possibility is that the yet unknown sequence(s) in
processed SOD dsRNA may be stimulating reactions similar to
RNA activation (RNAa) [56,57]. If this is indeed the case, this
would be a novel facet of RNAi in parasitic helminths. Although
the function of SOD as a protective anti-oxidant has been
suggested [58–60], its essential role in parasite development has
not been established. If the overexpression response seen in this
study is linked to SOD depletion or SOD sequence activation, this
would imply a critical role in sporocyst survival, and perhaps in
larval development as evidenced by its association with the
sporocyst size phenotype. The role of endogenous SOD, and other
anti-oxidants, in sporocysts confronted with oxidative stress is the
subject of ongoing investigations in our laboratory.
To date, RNAi is the only reverse genetic tool available in
schistosomes [22], and although it has been successfully applied as a
functional genomics tool in both mammalian [25,28,61] and snail
[26,27] stages of infection, a lack of consistency in the RNAi-
induced knockdown and resulting phenotypes indicates a pressing
need to more fully investigate RNAi to gain a better understanding
of this complex mechanism in S. mansoni, and other parasitic
flatworm species [31]. The results presented here provide an
overview of the variability that may be encountered as transcript-
specific dsRNA sequences are applied as a tool for targeted gene
manipulation and morphological phenotyping in larval schisto-
somes. It is anticipated that further improvements in dsRNA
delivery methods likely would be beneficial in attaining more
consistent transcript/protein knockdowns and resulting phenotypes,
as will further detailed analyses of specific siRNA for individual
genes. Future studies involving optimization of transfection reagent-
and electroporation-based gene delivery approaches are currently
being planned. In assessing RNAi effects, in addition to low and/or
inconsistent dsRNA penetrance, we also are hindered by the
numbers of parasites that can be processed for dsRNA treatments at
a given time,and, as reported in this study,a very limited phenotype
repertoire, due to a lack of more sensitive detection tools. These
restrictions illustrate some of the limitations facing large-scale RNAi
experiments, and demonstrate the necessity of small-scale or gene-
by-gene characterizations, until development of more sensitive,
higher-throughput methodologies [44].
In summary, this study is the first to provide a multi-gene
assessment of the efficacy of dsRNA treatments in characterizing
phenotypic and transcriptional changes brought about by
introduction of gene-specific dsRNAs into cultured S. mansoni
larvae. Prolonged exposure to dsRNA, when selectively applied to
target genes expressed in early larval stages, can generate
significant transcript knockdown, thus facilitating the investigation
of potential gene-associated function. However, as shown in the
present study, individual genes may differ significantly in their
abilities to render RNAi-like effects, and this is likely due, at least
partially, to efficacy of their intracellular processing. Although
RNAi approaches continue to be potentially valuable tools for
functional genomics in parasitic helminths, caution should be
taken in the design, set-up and execution of RNAi experiments. As
a followup to this study, we are now focusing on the group of
enzymes involved in reduction-oxidation (redox) reactions,
especially those with antioxidant activity, and that have exhibited
consistent transcriptional knockdown by RNAi. These functional
studies were made possible by the data provided in this initial
multi-gene profiling of dsRNA effects.
Supporting Information
Dataset S1 Target genes and primers. Table 1: List of genes
targeted in the RNAi screening, includes specific forward and
Figure 8. Observations of differential expression of EF1a protein levels in S. mansoni sporocysts after dsRNA treatments.
Immunfluorescence photomicrographs of GFP dsRNA (control; A) and EF1a dsRNA (B) treated sporocysts showing EF1a protein-knockdown post
RNAi treatments. Larvae were cultured with dsRNAs for 7 days and fixed prior to treatment with anti-EF1a antibody and Alexa 488-conjugated
secondary antibody. Strong immunoreactivity (green fluorescence) is distributed among various cells and tissues within interior of control sporocysts
(A), compared to only weak reactivity in EF1a dsRNA-treated sporocysts (B). Confocal images; 4006.N=2 .
doi:10.1371/journal.pntd.0000502.g008
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www.plosntds.org 11 August 2009 | Volume 3 | Issue 8 | e502reverse primers used to amplify the 500 bp templates for dsRNA
synthesis. Also, protein functions were included in the context of S.
mansoni when possible. Gb: GenBank. Table 2: List of primers used
to quantify specific transcripts during real-time Q-PCR analysis.
Found at: doi:10.1371/journal.pntd.0000502.s001 (0.12 MB XLS)
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